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50 Poster Session IThe median follow up is 13.5 months (15.2 months among survi-
vors, range 4.1–22.3 months). 100-day treatment-related mortality
was 10.3%, without any VOD or TMA. One and two year relapse-
free survival is 56.9% and 45.6% and overall survival is 74.8% and
69.8% at 1 and 2 years. Causes of death include sepsis(4), relapse(2),
and EBV-PTLD(2). Chimerism analysis at day 100 (n 5 23) re-
vealed complete single cord chimerism in 13 subjects with mixed
chimerism in 10. The first infused unit was the predominant unit
at day 100 in 15/23 subjects. There was no correlation between
cord dominance and HLA match, TNC/kg or CD341 cell count.
Conclusions: This study demonstrates excellent engraftment after
DUCBT using a reduced-intensity conditioning regimen. The risk
of acute and chronic GVHD are low when sirolimus and tacrolimus
are used as GVHD prophylaxis, and survival is comparable to his-
torical unrelated donor cohorts.131
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Killer Ig-like receptors (KIRs) are expressed on human NK and
T cell subsets. KIRs transmit either inhibitory or activating signals
regulating cell activities. Some inhibitory KIRs specifically recog-
nize HLA-A, B, or Cw allotypes on target cells as inhibitory KIR
ligands (iKIRLs). Most activating KIR ligands have not yet to be
well defined. We have analyzed the known iKIRLs and KIR geno-
types in 544 primary allogeneic HCTs with T-replete grafts from
unrelated or HLA mismatched related donors. There were 159
transplants with class I antigen level mismatched donors; 79 cases
were without also being iKIRL mismatched; 80 cases were mis-
matched for the iKIRLs. The latter group had inferior overall sur-
vival (HR: 1.79; P 5 0.003), and event-free survival (HR: 1.86; P
5 0.001). Both relapse (HR: 1.90; P 5 0.03) and non-relapse mor-
tality (HR: 1.83; P 5 0.01) contributed to the inferior survival of
the group that were mismatched for both Class I and iKIRLs. The
detrimental effect was also evident when 8/8 antigen-matched
transplants (385) were analyzed for patients lacking iKIRLs. Over-
all survival in patients (218) lacking the HLA-Cw Group-1 or 2
iKIRL was significantly lower than that in patients (167) having
the iKIRLs, (HR: 1.39; P 5 0.02). Patients lacking iKIRLs had
higher non-relapse mortality (HR: 1.50; P 5 0.03). KIR genotype
data are available for 360 cases so far. Our algorithm calculates
a score based on the KIR genotype of the patient compared to
the KIR genotype of the donor. In 360 cases the score was found
to be predictive of the incidence of aGVHD (Table). Multivariate
analyses confirmed that both iKIRLs and KIR genotype scores
were independent factors affecting HCT outcomes. In T-replete
HCT, iKIRL mismatches, as well as the absence of iKIRLs confer
higher risk of a poor outcome. The algorithm for KIR genotype
scoring produces results that are predictive of the incidence of
aGVHD.
Correlation of SCORE and aGVHD
aGVHDScore 0 I II III IV III1(%).1 12 5 12 14 8 43
1 15 12 19 10 18 38
0 to 21 41 40 34 28 21 30
\21 34 12 12 8 7 21Chi Square test 5 0.00271.132
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Background: Total body radiation (TBI) conditioning is associ-
ated with substantial toxicity in patients (pts) undergoing haploi-
dentical stem cell transplantation (HaploSCT). We evaluated
a chemotherapy-only reduced-intensity conditioning (RIC) regi-
men to elicit engraftment with less toxicity in patients with AML/
MDS treated with HaploSCT and report a non-randomized com-
parison between FMT and TBI regimens for such patients.
Methods: 31 pts underwent HaploSCT with CD34-selected
PBPC. 18 pts received a RIC consisting of melphalan 140 mg/m
sq on day -8, 10 mg/m2, thiotepa on day -7, 160 mg/m2, fludarabine
on days -6, -5, -4, -3 and 1.5 mg/kg of rabbit ATG on days -6, -5, -4,
and -3 (FMT) between 10/2001–4/2007, and 13 pts who received
thiotepa 5 or 10 mg/kg on day -8, cyclophosphamide 60 mg/kg
on days -7 and -6, ATG 15 mg/kg on days -4 and -3 and TBI
3Gy/day on days -4 to -1 (CTT) between 4/1995–2/2000. The me-
dian age was 36 and 35 years respectively. Cytogenetics were poor
or intermediate-risk with the poor-risk present in 55.5% of FMT
and 43% CTT pts. At the time of transplant 61.1% of FMT and
53.8% of CTT pts had relapsed/refractory disease. Pts had 2 or
3-antigen mismatched donors with 3-antigen mismatch in 77%
FMT and 53.8% CTT pts. The numbers of CD34 cells infused
were 11 and 7.3  106/kg (p 5 0.4), and CD3 cells were 0.01 and
0.85  104/kg (p 5 0.1) in the FMT and CTT groups. 4 out of
13 pts in the CTT group also received psoralen-phototherapy
treated T-cells. Results: Median follow-up in FMT pts was 30.5
months. 77.8% and 71.4% of the pts engrafted with FMT and
CTT regimens. Grade 3–4 aGVHD occurred in 5.5% and 57.1%
(p 5 0.002) while cGVHD was found in 27.7% and 42.5%
(p5NS). Early death occurred in 1 FMT and 6 CTT pts (p 5
0.018) while day 100 TRM was 16.6% versus 53.5% (p 5 0.028).
OS was 33.3% and 14.3% (p5 0.06). 4 out of 7 (57%) FMT treated
pts in CR at the time of transplant survived as compared with 2 out
of 11 pts (18.1%) not in CR (p 5 0.03). None of the 6 pts in CR
treated with CTT survived (p 5 0.03). NRM was 33% in the
FMT group and 69% in the CTT group. 1 pt died of GVHD in
the FMT group as compared with 4 in the CTT group. Other
causes of death were disease relapse in 6 pts, organ failure and infec-
tions in 5 pts in the FMT group, while 3 pts died of recurrent disease
and 4 of infection and organ failure in the CTT group.
In conclusion, the RIC FMT regimen was an effective, less toxic
preparative regimen for patients with AML undergoing HaploSCT.133
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Cell dosage is critical for cord blood transplantation (CBT) out-
come; therefore pediatric patients are ideal for CBT. Younger re-
cipient age is associated with better survival and neutrophil
(ANC500) engraftment. Outcome is furter improved by increasing
CB cell dose. Most CB banks practice red blood cell (RBC) reduc-
tion, which incur significant nucleated and progenitor cell loss after
processing. One way to minimize cell loss and reduce volume is to
